Order Article Reprints

Imran M, Arora MK, Chaudhary A, Khan SA, Kamal M, Alshammari MM, Alharbi RM, Althomali NA, Alzimam IM, Alshammari AA, et al. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. Biomedicines. 2022; 10(11):2793. https://doi.org/10.3390/biomedicines10112793

Imran, Mohd., Mandeep Kumar Arora, Anurag Chaudhary, Shah Alam Khan, Mehnaz Kamal, Manal Mutlaq Alshammari, Raghad Mohammad Alharbi, Nuha Abdullah Althomali, Ibrahim Mohammed Alzimam, Abdullah Ayed Alshammari, and et al. 2022. "MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature" Biomedicines 10, no. 11: 2793. https://doi.org/10.3390/biomedicines10112793

Imran, M., Arora, M. K., Chaudhary, A., Khan, S. A., Kamal, M., Alshammari, M. M., Alharbi, R. M., Althomali, N. A., Alzimam, I. M., Alshammari, A. A., Alharbi, B. H., Alshengeti, A., Alsaleh, A. A., Alqahtani, S. A., & Rabaan, A. A. (2022). MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. Biomedicines, 10(11), 2793. https://doi.org/10.3390/biomedicines10112793